Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-95

PD stated at this exact time last year "the next 12 months will be transformational for painchek"

I'd now like an explanation for that comment. SP has dropped 50% and there's been no transformation whatsoever. I'll get the usual cock jockeys mentioning the pandemic but this comment was made during the pandemic. There is positives on the quarterly revenue for receipts from customers but hardly transformational. Was he expecting FDA approval by now to make this comment? Why has It been delayed by over a year? Trial hasn't even started yet.